Related Articles
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
MHC class I down-regulation: tumour escape from immune surveillance? (Review)
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy
Constitutive expression of IRF-5 in HTLV-1-infected T cells
HUB1 is an autoantigen frequently eliciting humoral immune response in patients with adult T cell leukemia.